Description
ATWLPPR Peptide TFA, a heptapeptide, acts as a selective neuropilin-1 inhibitor, inhibits VEGF165 binding to NRP-1, used in the research of angiogenesis[1]. ATWLPPR Peptide TFA has potential in reducing the early retinal damage caused by diabetes[2]